Takeda Pharmaceutical Company Limited

Jun Fujimoto

Douglas Robert Cary

Hiroshi Banno

Takaharu Hirayama

Yasuhiro Hirata

Koji Ono

Masahiro Ito

Toshio Tanaka

Hidekazu Tokuhara

Yasuyoshi Arikawa

Hironobu Maezaki

Yasuhiro Imaeda

Nobuki Sakauchi

Nobuo Cho

Moriteru Asano

Ryo Mizojiri

Akinori Toita

Hironori Kokubo

Nao Morishita

Xin Liu

Takuto Kojima

Yasutomi Asano

Terufumi Takagi

Masanori Okaniwa

Osamu Kurasawa

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Jun Fujimoto